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Monitoring of asthma control can be performed with different means including measurement
of the concentration of nitric oxide (NO) in exhaled air. Due to its action on the NO-metabo-
lism; we hypothesized that the intake of Sildenafil might augment and falsify the NO-values
in exhaled air of subjects taking the drug to treat erectile dysfunction.
This randomised, placebo-controlled cross-over study including 10 male non-asthmatic
volunteers taking a single dose of 50 mg Sildenafil did not confirm this assumption in non-asth-
matic subjects. We cannot think of any reason why asthmatics should behave differently.
On the basis of these results, it does not seem necessary to ask asthma patients with
elevated NO-values if they had taken any selective inhibitor of the cGMP-specific phosphodies-
terase Type 5 as Sildenafil prior to the test.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Nitric oxide (NO) acts via its second messenger cGMP as
a pulmonary vasodilator. Inhibition of the cGMP-specific
phosphodiesterase type 5 leads to an accumulation of cGMP
enhancing the action of NO. Sildenafil, a selective inhibitor
of this phosphodiesterase, augments the relaxation of1 4144103.
.ch (T. Rothe).
9 Elsevier Ltd. All rights reservedsmooth muscle cells in pulmonary blood vessels, in the
erectile tissue of the penis, and in other small vessels. Due
to this effect pulmonary artery pressure may decrease in
pulmonary hypertension,1 filling of the erectile tissue
enhances with consecutive improvement of erectile func-
tion, and nasal blood flow increases causing nasal
congestion.
The upper limit of the normative value of NO-concen-
tration of exhaled air is 20 ppb2 (measured at an expiratory
flow rate of 50 ml/sec). An elevated NO-concentration in
asthma reflects the degree of eosinophilic inflammation in
the bronchial mucosa.3 Exhaled NO-concentration has.
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control. A rise of NO surpassing a concentration of >35 ppb
and a sudden rise of more than 30% may indicate the
beginning of an asthmatic exacerbation.4,5
Several factors influence the NO-concentration in
exhaled air. A transient decline of the NO-concentration
may occur after vigorous exercise, alcohol consumption,
and with cigarette smoking.6 Permanent low levels are
found in individuals suffering from cystic fibrosis,7 primary
ciliary dyskinesia,8 and in some cases of pulmonary arterial
hypertension.9 In contrast, viral infection of the
airways,10,11 bronchiolitis obliterans syndrome (BOS),12
allergic rhinitis, and the intake of a nitrate-rich meal13 may
augment the NO-concentration.
In patients suffering from pulmonary arterial hyperten-
sion and having low levels of NO in exhaled air, treatment
with bosentane decreases pulmonary arterial pressure and
leads to a rise of the exhaled NO-concentration.14 Phos-
phodiesterase-inhibitors as Sildenafil have been shown to
be active in lowering pulmonary arterial pressure too.1
These drugs, acting on the NO/cGMP e metabolism, might
lead to a comparable rise of NO-concentration in exhaled
air as it was observed in 4 individual cases of patients with
pulmonary arterial hypertension.15 This effect could
possibly falsify the values of NO being measured when
monitoring asthmatic patients because asthma occurs in
elderly men too who may take a drug like Sildenafil to treat
erectile dysfunction.
This randomised, cross-over and placebo-controlled
study intended to clarify in what way Sildenafil influences
the values of exhaled NO-concentration in non-asthmatic
individuals. In this preliminary study we chose non-asth-
matics assuming that they have a lesser variation in NO-
values facilitating the detection of a significant rise in NO.
Material and methods
The trial had been approved by the local ethics committee
of the canton of Valais. Potential side effects of the study
medication were covered by Zurich Insurance, Switzerland.
All volunteers gave written informed consent.
Subjects
Young and healthy male staff members of our clinic were
screened for having a negative personal history regarding
bronchial asthma, symptomatic allergies, pulmonary
arterial hypertension, and coronary heart disease. They
were included in the study only when denying the intake
of any drugs acting as NO-donators (nitroglycerine,
nebivlolum, etc.) and of any selective inhibitor of the
cGMP-specific phosphodiesterase Type 5. Smokers and ex-
smokers having quitted smoking less than 6 months ago
were excluded too. Each applicant performed a spirom-
etry. Values of FEV1 and FVC had to be within normal
limits. The first 10 candidates of the screening, fulfilling
all criteria, entered the trial. When starting the trial
phase, all volunteers were asked for signs of airway
infection. In case of infection, entering, respectively
continuation of the trial was postponed for one week after
cessation of symptoms.Methods
The volunteers were instructed to avoid nitrate-rich meals
for at least 3 days prior to day 1 of the testing, between day
1 and day 7, and for the next 3 days following day 7.
Additionally, they were informed not to drink alcoholic
beverages for at least 1 day and to avoid vigorous exercise
at least for 6 h prior to the NO-tests on day 1 and day 7. To
facilitate the resorption of Sildenafil, the volunteers had
only a light breakfast avoiding the ingestion of fat for 2 h
prior to the intake of the test drug and for the first 30 min
following their intake. In two cases the testing had to be
postponed by two weeks due to symptoms of acute viral
infection of the upper airways. A third volunteer having
participated in day 1e3 of the trial could not continue the
trial on day 7 due to an acute rhinitis. He left the service of
our clinic before the rhinitis was cured and was replaced by
an eleventh volunteer.
Study design
We received Sildenafil 50 mg tablets directly from the
manufacturer. They were crushed with a mortar to
a powder being filled into non transparent gelatine capsules
within 4 weeks prior to the beginning of the study.
Mannitol, serving as placebo, was filled into identically
looking gelatine capsules. The verum and placebo capsules
had been prepared by the pharmacy of the cantonal
hospital of Lucerne. To blind volunteers and the nurse
performing the NO-tests, Sildenafil and placebo capsules
were coded on the basis of a randomisation list, so that
neither the volunteers nor the nurse knew on what day and
in which order Sildenafil and placebo were administered to
each individual patient.
The study started on 1st November 2006. NO-testing took
always place at around 8.00 a.m. On day 1, half of the
volunteers received each one capsule containing 50 mg of
Sildenafil, and the other volunteers received each one
capsule containing Mannitol. On day 7, the volunteers having
received Sildenafil on day 1 were given now a capsule con-
taining placebo and vice versa. NO-concentration in exhaled
air was measured before and 1 h after intake of the capsule
on day 1 andday 7, aswell as 24 and 48 h after theNO-tests on
day 1 and day 7. The capsules were taken under supervision
of the nurse performing the tests.
NO-detection method
NO-concentration inexhaled air expressed inparts per billion
(ppb) was measured with the NIOX MINO (Aerocrine AB,
Solna, Sweden) according to the manufacturer’s directives.
Using this device, exhaled NO is quantified at an expiratory
flow rate of 50 ml/sec.16 All volunteers were trained to
perform NO-testing correctly prior to the trial phase.
Statistical analysis
The case report of Lee et al.14 reported a mean increase of
exhaled NO of 5 ppb after oral intake of 50 mg Sildenafil in 4
volunteers. Due to these preliminary results, we assumed
an increase of 5 ppb as our benchmark effect size.
Table 1 Descriptive statistics of different measurements by group (1 two-sample t-test comparing the means of the two
groups).
Group Placebo e Verum Group Verum e Placebo
Mean SD Mean SD
Verum, pre-test 23.0 4.5 16.2 6.4
Change Verum, after 1 h 0.8 3.2 1.2 2.1
Change Verum, after 24 h 1.3 4.1 0.5 3.4
Change Verum, after 48 h 1.0 2.9 0.0 6.1
Placebo, pre-test 20.5 5.7 16.0 6.1
Change Placebo, after 1 h 2.0 1.4 0.2 1.6
Change Placebo, after 24 h 3.8 4.1 0.2 4.9
Change Placebo, after 48 h 1.5 3.4 1.4 2.3
Table 2 Descriptive statistics of different measurements
of the entire sample.
Difference to
Pre-test level
Entire sample
p1 Mean SD p2
Verum, 1 h 0.83 1.0 2.4 0.22
Placebo, 1 h 0.09 0.9 1.7 0.13
Verum, 24 h 0.54 0.4 3.6 0.78
Placebo, 24 h 0.25 1.6 4.7 0.31
Verum, 48 h 0.81 0.6 4.1 0.73
Placebo, 48 h 0.20 0.1 3.1 0.92
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question if Sildenafil possibly influences the NO-concentra-
tion inexhaledair, it is important to knowthe rangeof normal
values of exhaled NO and to know normal day-to-day vari-
ability. According to a study2 using the same device, the
normal values of exhaled NO in non-allergic and non-asth-
matic adults lie between 5 and 20 ppb (at 50 ml/sec flow
rate). One member of our staff did NO-testing once daily on
ten working days within a fortnight. The mean NO-value was
15.7 ppb; the standard deviation 2.5 ppb. Another staff
member suffering fromwell controlled asthma performed 10
NO-measurementswithin 24 h. Themeanvaluewas 22.6 ppb;
the standard deviation 1.35 ppb. A recent paper17 demon-
strated a pooled standard deviation for NO of 2.1 ppb in non-
allergic and non-asthmatic subjects.
Based on this information and assuming a within-subject
standard deviation of 3 ppb, we found that 5 subjects per
arm were sufficient to enable confirmation of a benchmark
effect of 5 ppb by a statistically significant result with
a probability of 90% in a cross-over analysis controlling for
potential period effects by means of a 2-sample t-test.
On the basis of the raw data we calculated the mean pre-
and post-treatment NO-values at day 1 and day 7 in the two
groups, as well as the 1s-intervall. We named the group of
volunteers taking placebo on day 1 and Sildenafil on day 7
‘‘placeboeverum Z PV-group’’ and the one starting with
Sildenafil on day 1 ‘‘VP-group’’. Pre- and post-treatment
valueswere comparedwithin subjects using the paired t-test
and between the two groups of subjects using the two-
sample t-test. The same procedure was performed with the
NO-values obtained 24 and 48 h after day 1 and day 7.
The main analysis involved the individual changes di in
post-test values of NO from the first to the second period,
whichwere comparedbetween the twogroups using the two-
sample t-test. The expression [meanPV(di)  meanVP(di)]/2
provides an unbiased estimate of the treatment effect.
Conversely, period effects can be estimated by the expres-
sion [meanPV(di) þ meanVP(di)]/2.18 These analyses were
repeated with the corresponding baseline-adjusted differ-
ences. All statistical tests were two-sided and based on
a significance level of 0.05.
Results
The mean age of the analysed subjects was 35 years with
a range from 19 to 51 years and did not differ within thetwo groups. Unfortunately, due to the shift plans of the
volunteers, it was not always possible to obtain all NO-
values 24 and 48 h after day 1 and day 7.
The mean pre-treatment NO-values in the PV-group on
day 1 and 7 were 23 ppb (verum), and 20.5 ppb (placebo)
respectively. In the VP-group the pre-treatment NO-values
were 16.2 ppb (verum) and 16.0 (placebo) respectively.
The 1 h post-treatment NO-values in the PV-group were
23.8 ppb (verum) and 22.5 ppb (placebo) respectively
17.3 ppb (verum) and 16.2 (placebo) in the VP-group. These
values and the NO-values measured after 24 and 48 h are
shown in Table 1. The differences in these pre-test and
post-test values between the two groups were not
significant.
Table 2 shows the mean differences of NO-values
between post-test and pre-test levels. In the entire sample
the mean difference was 1.0 ppb (SD 2.4 ppb) for verum
(sildenafil 50 mg) respectively 0.9 ppb (SD 1.7 ppb) for
placebo.
Effects of treatment (verum vs. placebo) and of period
were estimated for 1 h, 24 h, and 48 h after intake of the
respective capsule. Estimates with and without adjustment
for pre-test levels are reported. The 95%-confidence
intervals show that none of the effects were statistically
significant (Table 3).
Compared to placebo, Sildenafil 50 mg did not lead to an
increase in exhaled NO, neither 1 h, nor 24 h, respectively
48 h after intake of the capsules. Moreover, in none of the
cases the upper limit of the 95%-confidence interval
reached the assumed benchmark level of 5 ppb. Only if the
confidence intervals were adjusted for the multiplicity of
time points considered, did one of them reach slightly
beyond 5 ppm (results not shown).
Table 3A Estimated treatment and period effects (with 95%-confidence intervals)a at the different post-intervention times.
Effect After 1 h After 24 h After 48 h
Treatmentb Unadjusted 1.21 (1.54, 3.96) 1.63 (7.38, 4.13) 0.83 (2.59, 4.25)
Adjustedd 0.13 (2.43, 2.18) 2.75 (9.25 to 3.75) 0.42 (3.51, 2.68)
Periodc Unadjusted 0.04 (2.71 to 2.80) 0.88 (6.63 to 4.88) 0.83 (4.25, 2.59)
Adjustedd 1.12 (3.43 to 1.18) 2.25 (8.75, 4.25) 2.08 (5.18, 1.01)
Treatment effects: [mean of changes in group PV  mean of changes in group VP)/2, period effects: [mean of changes in group
PV þ mean of changes in group VP]/2.
V Z Verum, P Z Placebo.
a Effects were estimated based on the group means of individual changes in corresponding measurements from period 1 to period 2.
b Verum vs. Placebo.
c Second vs. first treatment period.
d In all calculations, values measured after administration of the respective capsule were replaced by their differences to the baseline
value of the same period.
Table 3B Estimated treatment effects (with Conferring-corrected 95%-confidence intervals)a at the different post-inter-
vention times.
Effect After 1 h After 24 h After 48 h
Treatmentb Unadjusted 1.21 (2.39, 4.81) 1.63 (9.36, 6.11) 0.83 (3.87, 5.53)
Adjustedc 0.13 (3.14, 2.89) 2.75 (11.48 to 5.98) 0.42 (4.67, 3.83)
Treatment effects: [mean of changes in group PV  mean of changes in group VP)/2, period effects: [mean of changes in group
PV þ mean of changes in group VP]/2.
a Effects were estimated based on the group means of individual changes in corresponding measurements from period 1 to period 2.
Confidence intervals were corrected for the three parallel comparisons by choosing a confidence level of 0.9833 instead of 0.95.
b Verum vs. Placebo.
c In all calculations, values measured after administration of the respective capsule were replaced by their differences to the baseline
value of the same period.
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measurements are shown in Fig. 1.
Discussion
The late phase of IgE-mediated allergic inflammation in
asthma is associated with an eosinophilic infiltration of the
mucosa. In some forms of non-allergic adult-onset asthma
too, especially when aspirin-sensitivity and nasal polyposis
can be demonstrated, eosinophils are the main inflamma-
tory cells involved.19 The NO-concentration of exhaled air
correlates well with the degree of sputum eosinophilia.
Asthmatic exacerbations due to allergen exposure20 and
exacerbations due to inadequate lowering of the anti-
inflammatory treatment with corticosteroids lead to
a significant rise of NO-values in exhaled air.2 NO-
measurement is being used more and more in diagnosing
asthma, assessing corticosteroid response,21 and moni-
toring asthma control to detect asthmatic exacerbation
earlier.22 Different factors may interfere with this tech-
nique and augment the NO-level in exhaled air as a nitrate-
rich meal like spinach does.
A considerable number of elderly male asthma patients
will suffer from erectile dysfunction too and may therefore
take drugs as Sildenafil. In a report of 4 individuals having
taken Sildenafil an increase of NO-concentration in exhaled
air had been observed.15 The purpose of this study was to
find out if the intake of Sildenafil or of another selective
inhibitor of the cGMP-specific phosphodiesterase Type 5
falsely augments NO-values in exhaled air. This wouldreduce the specificity of NO as a marker of an early asth-
matic exacerbation. Not acting as an NO-donator, Sildenafil
cannot augment the NO-concentration directly. However, it
may do so indirectly by inhibiting the degradation of its
second messenger.
This randomised, placebo-controlled cross-over trial with
10 male volunteers was not able to detect a significant rise
of exhaled NO after the intake of a single dose of 50 mg
Sildenafil. Different reasons may explain this finding. It
seems likely that selective inhibitors of the cGMP-specific
phosphodiesterase Type 5 do not augment NO-concentration
in exhaled air. This view is reinforced by the study of Sartori
who was able to show that vascular NO-synthesis did not
appear to be reflected by exhaled NO-values.23 Based on this
finding we consider it as unlikely that a higher dosage of
Sildenafil would have augmented exhaled NO in our study.
We had chosen to use 50 mg because this is the dosage most
often used in the treatment of erectile dysfunction and
because 50 mg had been the dosage taken in the above
mentioned case report published by Lee.15 With our study
examining the effect of a single dose of Sildenafil we cannot
for certain exclude a long-term effect on exhaled NO with
regular treatment as it had been shown in patients with
pulmonary hypertension and low exhaled NO-values after 7
months of treatment with bosentan.14 However, the mech-
anism of action is different for bosentan compared to sil-
denafil making it less likely that regular dosing of Sildenafil
would have changed the results of our study.
In a recent large general population sample in Sweden
the mean exhaled NO-concentration was 16 ppb.24
Figure 1 Individual time courses of exhaled NO across the
eight measurements (i.e. before and 1, 24 and 48 h after intake
of the respective capsule in each of the two periods) (Legend
to the figure: The period during which verum (placebo) was
administered is represented by solid (dashed) lines).
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being excluded, the mean NO at day 1 respectively day 7
prior to the intake of the drugs was higher with mean values
between 16 and 23 ppb. Therefore, doubts may come up if
there was not some hidden allergy, sinus problem or minor
symptoms of viral infection of the upper airways among our
volunteers. Each of them had performed a normal spirom-
etry prior to inclusion into the study and the personal
history had been taken to exclude asthma, allergy, flu-like
symptoms, non-smoking status, etc. However, we did not
search more profoundly for allergy and asthma. This fact
may weaken our results. However, the main causes of
allergies of the airways, pollen and mite, could not have
interfered with the study taking place in late November in
a mite-free surrounding in the Swiss alps at 1500 m above
sea level. The higher NO-values in our volunteers might be
just a result of this altitude. The study of Duplain had
shown an increase of exhaled NO at 4.500 m.25
Bronchial constriction may lower the exhaled NO-
concentration26 significantly. To avoid interference with
variable bronchial muscular tone we had chosen volunteers
with a normal spirometry prior to the study and a negative
history regarding doctor’s diagnosed asthma. However, we
neither did perform a methacholine challenge nor consec-
utive spirometry measures on each day of NO-testing.
The relatively high NO-levels of our volunteers at 8.00
a.m. raise the question if a circadian rhythm of exhaled NO
may exist. It is known that hyperventilation, i.e. in the
frame of sports activities, lowers the exhaled NO-values.
During the night, the ventilation of the lungs is minimal.
Due to reduced ventilation measuring NO early in the
morning may give higher results than in the afternoon when
daily activities have increased minute ventilation. But
contrarily, one paper described a circadian rhythm of
exhaled NO with low levels during night time.27
In two of our volunteers the trial phase had to be post-
poned for 2 weeks due to an acute viral infection of the upper
airways. We do not know if this latency was long enough to
lower the virus-induced enhancement of expired NO within
the limits of normal again. However, such intra-individual
fluctuations should be of little influence if post-interventionvalues are adjusted for the baseline values of the respective
period. And indeed, estimates based on adjusted values were
even less suggestive of a positive treatment effect. The same
argument applies to potential carry-over effects from the
first to the second period. Although such effects are very
unlikely with a wash-out period of 7 days, they would anyway
be controlled by the use of adjusted values.
There is the issue of generalizability of our results,
notably also to men of a higher age. This is an important
concern. However, we think that a cross-over study is
slightly less prone to selection effects than a study with
separate treatment arms because every subject acts as its
own control.
The case report of Lee15 reporting elevated expiratory
NO after 50 mg Sildenafil was based on patients with
pulmonary hypertension. Our volunteers did not suffer from
pulmonary hypertension, which might explain why we
found no evidence of an increase in NO.
One limitation is the small sample size which led to esti-
mates with a considerable amount of uncertainty. Never-
theless, none of the 95%-confidence intervals of our
treatment effect estimates reached beyond 5 ppb, the
benchmark effect size we had assumed in our sample size
calculation.
Themajor possible flawof our study is the fact that we did
not perform it with asthmatics. But, with asthma patients,
due to higher values and a higher variability of exhaled NO,
we would have had to investigate much more than 10
subjects. We are not aware of any reason why patients with
asthma should react differently to Sildenafil than subjects
not suffering from the disease.
Based on our results and the data from the work of Sar-
tori,22 a complementary study to test the effect of Sildenafil
on exhaled NO-levels in asthmatic subjects is not mandatory.
We don’t consider it important to know if a male asthma
patient has taken any selective inhibitor of the cGMP-
specific phosphodiesterase Type 5 as Sildenafil prior to an
NO test. Therefore, that question possibly offending
patients can be avoided.
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